Metal complex SERMs (selective oestrogen receptor modulators). The influence of different metal units on breast cancer cell antiproliferative effects (Q36364465)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Metal complex SERMs (selective oestrogen receptor modulators). The influence of different metal units on breast cancer cell antiproliferative effects	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

13 August 2017

1 reference

Europe PubMed Central

Metal complex SERMs (selective oestrogen receptor modulators). The influence of different metal units on breast cancer cell antiproliferative effects (English)

1 reference

Europe PubMed Central

13 August 2017

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

2

object named as

Siden Top

1 reference

Europe PubMed Central

13 August 2017

author name string

Anne Vessières

1

1 reference

Europe PubMed Central

13 August 2017

Wolfgang Beck

3

1 reference

Europe PubMed Central

13 August 2017

Elizabeth Hillard

4

1 reference

Europe PubMed Central

13 August 2017

Gérard Jaouen

5

1 reference

Europe PubMed Central

13 August 2017

language of work or name

0 references

publication date

27 September 2005

1 reference

Europe PubMed Central

13 August 2017

Dalton Transactions

1 reference

Europe PubMed Central

13 August 2017

4

1 reference

Europe PubMed Central

13 August 2017

529-541

1 reference

Europe PubMed Central

13 August 2017

Contraceptive applications of estrogen

1 reference

https://api.crossref.org/works/10.1039%2FB509984F

21 January 2018

A comparison of the effects of raloxifene and conjugated equine estrogen on bone and lipids in healthy postmenopausal women.

1 reference

https://api.crossref.org/works/10.1039%2FB509984F

21 January 2018

Hormonal treatment of postmenopausal women

1 reference

https://api.crossref.org/works/10.1039%2FB509984F

21 January 2018

Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial

1 reference

https://api.crossref.org/works/10.1039%2FB509984F

21 January 2018

In vivo effects of estrogen on human brain.

1 reference

https://api.crossref.org/works/10.1039%2FB509984F

21 January 2018

Toward checkmate: biology and breast cancer therapy for the new millennium

1 reference

https://api.crossref.org/works/10.1039%2FB509984F

21 January 2018

The development of tamoxifen for breast cancer therapy: a tribute to the late Arthur L. Walpole

1 reference

https://api.crossref.org/works/10.1039%2FB509984F

21 January 2018

Antiestrogens--tamoxifen, SERMs and beyond

1 reference

https://api.crossref.org/works/10.1039%2FB509984F

21 January 2018

Annual report to the nation on the status of cancer, 1975-2001, with a special feature regarding survival

1 reference

https://api.crossref.org/works/10.1039%2FB509984F

21 January 2018

Effects of tamoxifen on bone mineral density and metabolism in postmenopausal women with early-stage breast cancer

1 reference

https://api.crossref.org/works/10.1039%2FB509984F

21 January 2018

Hormonal therapy for breast cancer. An update

1 reference

https://api.crossref.org/works/10.1039%2FB509984F

21 January 2018

Endocrine therapy for advanced breast cancer: a review

1 reference

https://api.crossref.org/works/10.1039%2FB509984F

21 January 2018

ER beta: identification and characterization of a novel human estrogen receptor

1 reference

https://api.crossref.org/works/10.1039%2FB509984F

21 January 2018

Cloning of a novel receptor expressed in rat prostate and ovary

1 reference

https://api.crossref.org/works/10.1039%2FB509984F

21 January 2018

Estrogen receptor beta--a new dimension in estrogen mechanism of action

1 reference

https://api.crossref.org/works/10.1039%2FB509984F

21 January 2018

Human oestrogen receptor cDNA: sequence, expression and homology to v-erb-A

1 reference

https://api.crossref.org/works/10.1039%2FB509984F

21 January 2018

Structure-based virtual screening for plant-based ERbeta-selective ligands as potential preventative therapy against age-related neurodegenerative diseases

1 reference

https://api.crossref.org/works/10.1039%2FB509984F

21 January 2018

Estrogen receptor subtype-selective ligands: asymmetric synthesis and biological evaluation of cis- and trans-5,11-dialkyl- 5,6,11, 12-tetrahydrochrysenes

1 reference

https://api.crossref.org/works/10.1039%2FB509984F

21 January 2018

Pyrazole ligands: structure-affinity/activity relationships and estrogen receptor-alpha-selective agonists.

1 reference

https://api.crossref.org/works/10.1039%2FB509984F

21 January 2018

A new series of estrogen receptor modulators that display selectivity for estrogen receptor beta

1 reference

https://api.crossref.org/works/10.1039%2FB509984F

21 January 2018

Constrained phytoestrogens and analogues as ERbeta selective ligands

1 reference

https://api.crossref.org/works/10.1039%2FB509984F

21 January 2018

Current and future status of adjuvant therapy for breast cancer

1 reference

https://api.crossref.org/works/10.1039%2FB509984F

21 January 2018

Antiestrogens and selective estrogen receptor modulators as multifunctional medicines. 1. Receptor interactions

1 reference

https://api.crossref.org/works/10.1039%2FB509984F

21 January 2018

Antiestrogens and selective estrogen receptor modulators as multifunctional medicines. 2. Clinical considerations and new agents

1 reference

https://api.crossref.org/works/10.1039%2FB509984F

21 January 2018

Insights into the molecular biology of the estrogen receptor define novel therapeutic targets for breast cancer

1 reference

https://api.crossref.org/works/10.1039%2FB509984F

21 January 2018

Molecular basis of agonism and antagonism in the oestrogen receptor

1 reference

https://api.crossref.org/works/10.1039%2FB509984F

21 January 2018

The structural basis of estrogen receptor/coactivator recognition and the antagonism of this interaction by tamoxifen

1 reference

https://api.crossref.org/works/10.1039%2FB509984F

21 January 2018

Structure of the ligand-binding domain of oestrogen receptor beta in the presence of a partial agonist and a full antagonist

1 reference

https://api.crossref.org/works/10.1039%2FB509984F

21 January 2018

Differential ligand activation of estrogen receptors ERalpha and ERbeta at AP1 sites

1 reference

https://api.crossref.org/works/10.1039%2FB509984F

21 January 2018

Molecular determinants for the tissue specificity of SERMs

1 reference

https://api.crossref.org/works/10.1039%2FB509984F

21 January 2018

Biomedicine. Defining the "S" in SERMs

1 reference

https://api.crossref.org/works/10.1039%2FB509984F

21 January 2018

The estrogen receptor enhances AP-1 activity by two distinct mechanisms with different requirements for receptor transactivation functions

1 reference

https://api.crossref.org/works/10.1039%2FB509984F

21 January 2018

Synthesis of boroxifen, a nido-carborane analogue of tamoxifen

1 reference

https://api.crossref.org/works/10.1039%2FB509984F

21 January 2018

Potent estrogen agonists based on carborane as a hydrophobic skeletal structure. A new medicinal application of boron clusters

1 reference

https://api.crossref.org/works/10.1039%2FB509984F

21 January 2018

Ring-substituted [1,2-bis(4-hydroxyphenyl)ethylenediamine]dichloroplatinum (II) complexes: compounds with a selective effect on the hormone-dependent mammary carcinoma

1 reference

https://api.crossref.org/works/10.1039%2FB509984F

21 January 2018

Estrogen-derived steroidal metal complexes: agents for cellular delivery of metal centers to estrogen receptor-positive cells.

1 reference

https://api.crossref.org/works/10.1039%2FB509984F

21 January 2018

What is the "best" platinum: cisplatin, carboplatin, or oxaliplatin?

1 reference

https://api.crossref.org/works/10.1039%2FB509984F

21 January 2018

Carboplatin versus cisplatin in solid tumors: an analysis of the literature

1 reference

https://api.crossref.org/works/10.1039%2FB509984F

21 January 2018

Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer.

1 reference

https://api.crossref.org/works/10.1039%2FB509984F

21 January 2018

Oxalato-platinum or 1-OHP, a third-generation platinum complex: an experimental and clinical appraisal and preliminary comparison with cis-platinum and carboplatinum

1 reference

https://api.crossref.org/works/10.1039%2FB509984F

21 January 2018

Antitumor activity of a new platinum complex, oxalato (trans-l-1,2-diaminocyclohexane)platinum (II): new experimental data

1 reference

https://api.crossref.org/works/10.1039%2FB509984F

21 January 2018

Tamoxifen derivatives for delivery of the antitumoral (DACH)Pt group: selective synthesis by McMurry coupling, and biochemical behaviour

1 reference

https://api.crossref.org/works/10.1039%2FB509984F

21 January 2018

Complexes of metals other than platinum as antitumour agents

1 reference

https://api.crossref.org/works/10.1039%2FB509984F

21 January 2018

Ti(IV) uptake and release by human serum transferrin and recognition of Ti(IV)-transferrin by cancer cells: understanding the mechanism of action of the anticancer drug titanocene dichloride.

1 reference

https://api.crossref.org/works/10.1039%2FB509984F

21 January 2018

Titanium(IV) targets phosphoesters on nucleotides: implications for the mechanism of action of the anticancer drug titanocene dichloride

1 reference

https://api.crossref.org/works/10.1039%2FB509984F

21 January 2018

Estrogen-Like Activity of Metals in Mcf-7 Breast Cancer Cells

1 reference

https://api.crossref.org/works/10.1039%2FB509984F

21 January 2018

Cadmium mimics the in vivo effects of estrogen in the uterus and mammary gland.

1 reference

https://api.crossref.org/works/10.1039%2FB509984F

21 January 2018

Synthesis, biochemical properties and molecular modelling studies of organometallic specific estrogen receptor modulators (SERMs), the ferrocifens and hydroxyferrocifens: evidence for an antiproliferative effect of hydroxyferrocifens on both hormone

1 reference

https://api.crossref.org/works/10.1039%2FB509984F

21 January 2018

Exploration of the bicyclo[3.3.1]nonane system as a template for the development of new ligands for the estrogen receptor.

1 reference

https://api.crossref.org/works/10.1039%2FB509984F

21 January 2018

Transcriptional regulation of the human quinone reductase gene by antiestrogen-liganded estrogen receptor-alpha and estrogen receptor-beta

1 reference

https://api.crossref.org/works/10.1039%2FB509984F

21 January 2018

Thirteen-week, repeated inhalation exposure of F344/N rats and B6C3F1 mice to ferrocene.

1 reference

https://api.crossref.org/works/10.1039%2FB509984F

21 January 2018

Synthesis and reactivity of a potential carcinogenic metabolite of tamoxifen: 3,4-dihydroxytamoxifen-o-quinone

1 reference

https://api.crossref.org/works/10.1039%2FB509984F

21 January 2018

Tamoxifen induced apoptosis in ZR-75 breast cancer xenografts antedates tumour regression

1 reference

https://api.crossref.org/works/10.1039%2FB509984F

21 January 2018

Ruthenium antimetastatic agents

1 reference

https://api.crossref.org/works/10.1039%2FB509984F

21 January 2018

Recent developments in the field of tumor-inhibiting metal complexes.

1 reference

https://api.crossref.org/works/10.1039%2FB509984F

21 January 2018

Inhibition of cancer cell growth by ruthenium(II) arene complexes

1 reference

https://api.crossref.org/works/10.1039%2FB509984F

21 January 2018

In vitro and in vivo activity and cross resistance profiles of novel ruthenium (II) organometallic arene complexes in human ovarian cancer

1 reference

https://api.crossref.org/works/10.1039%2FB509984F

21 January 2018

Selective estrogen receptor modulators in the ruthenocene series. Synthesis and biological behavior.

1 reference

https://api.crossref.org/works/10.1039%2FB509984F

21 January 2018

Selective estrogen-receptor modulators (SERMs) in the cyclopentadienylrhenium tricarbonyl series: synthesis and biological behaviour.

1 reference

https://api.crossref.org/works/10.1039%2FB509984F

21 January 2018

Identifiers

10.1039/B509984F

1 reference

Europe PubMed Central

13 August 2017

1 reference

Europe PubMed Central

13 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q36364465&oldid=1966902716"